Inventor · disambiguated record
Jiaqi Huang
Also filed as: HUANG JIAQI
15 granted patents·17 pending applications·57 citations·filing 2010–2025
92Inventor score
Files withCELLULAR BIOMEDICINE GROUP INC9ABELZETA INC7CELLULAR BIOMEDICINE GROUP HK LTD7SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD4MEDIMMUNE LLC2
Top patents by PatentIndex Score
32 records- 0196US11472858B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2021·Granted Oct 18, 2022·7 cites·4 claims
- 0296US11439665B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2021·Granted Sep 13, 2022·8 cites·4 claims
- 0395US11633430B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2022·Granted Apr 25, 2023·7 cites·5 claims
- 0495US11618778B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2022·Granted Apr 4, 2023·7 cites·6 claims
- 0595US11608369B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2022·Granted Mar 21, 2023·7 cites·6 claims
- 0695US11207349B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2020·Granted Dec 28, 2021·7 cites·5 claims
- 0794US11066457B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2018·Granted Jul 20, 2021·8 cites·8 claims
- 0893US12311022B2Bispecific chimeric antigen receptors targeting CD20 and BCMAABELZETA INC·Filed 2024·Granted May 27, 2025·2 cites·6 claims
- 0992US12458667B2Bispecific chimeric antigen receptors targeting CD20 and BCMAABELZETA INC·Filed 2024·Granted Nov 4, 2025·1 cites·4 claims
- 1090US12448432B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofABELZETA INC·Filed 2022·Granted Oct 21, 2025·1 cites·10 claims
- 1188US11498973B2BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2021·Granted Nov 15, 2022·1 cites·4 claims
- 1285US2025136707A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2024·Application pending·0 cites
- 1382US11142581B2BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2020·Granted Oct 12, 2021·1 cites·7 claims
- 1481US2023242613A1Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2023·Application pending·0 cites
- 1581US2024139243A1Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2023·Application pending·0 cites
- 1678US2025262243A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2025·Application pending·0 cites
- 1772US12338494B2Reagent and method for fluorescence quantitative real-time PCR detection of RCLABELZETA INC·Filed 2023·Granted Jun 24, 2025·0 cites·7 claims
- 1867US2023053305A1BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application ThereofSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2022·Application pending·0 cites
- 1964US11697848B2Reagent and method for fluorescence quantitative real-time PCR detection of RCLCELLULAR BIOMEDICINE GROUP INC·Filed 2019·Granted Jul 11, 2023·0 cites·7 claims
- 2060US2025144215A1Method for enriching tumor infiltrating lymphocytesABELZETA INC·Filed 2023·Application pending·0 cites
- 2157US2024115605A1Chimeric antigen receptors targeting cd20CELLULAR BIOMEDICINE GROUP INC·Filed 2022·Application pending·0 cites
- 2253US2023212255A1Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2021·Application pending·0 cites
- 2351US2024000839A1Bcma-targeted chimeric antigen receptorsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 2450US2023104705A1Combined chimeric antigen receptor targeting cd19 and cd20 and application thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2020·Application pending·0 cites
- 2549US2023181640A1Anti-bcma antibodies and chimeric antigen receptorsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 2649US2023144447A1Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereofSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 2749US2022380726A1Universal car-t cell and preparation and use thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2020·Application pending·0 cites
- 2839US2017275347A1Methods for identifying patients responsive to anti-pd-l1 antibody therapyMEDIMMUNE LTD·Filed 2015·Application pending·0 cites
- 2938US2013035249A1Methods and compositions for detecting and treating cea-expressing cancersMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 3038US2018079814A1Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancerMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 3134US9150927B2Quantification of IR-A and IR-B for tumor classificationHUANG JIAQI·Filed 2010·Granted Oct 6, 2015·0 cites·14 claims
- 3232US2011256155A1Methods to molecularly characterize circulating tumor cellsMEDIMMUNE LLC·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jiaqi Huang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →